Capecitabine and Pseudomonas Aeruginosa Combination in Metastatic Breast Cancer (MBC)

the efficacy of the combination is much better than monotherapy

Inclusion criteria

• Female between 18 and 70 years old
• Patients with histologic proved metastatic breast cancer, unsuitable to be treated locally.
• Patients with Her-2 negative breast cancer(HER-2 negative or one plus by IHC test , if HER-2 two plus by IHC,FISH result should be negative)
• Disease progression after anthracycline and/or taxane regimen therapy and candidate for capecitabine monotherapy
• Patients previously treated by capecitabine containing regimen should response to the chemotherapy containing capecitabine and progressed at least 4 months after the last capecitabine treatment
• Karnofsky score more than 70；ECOG 0~2；
• Normal functions with heart, liver,renal and bone marrow
• WBC≥4×109/L；Hb≥90 g/L；plt≥100×109/L
• Got ICF before enrollment

Exclusion criteria

• Pregnant or breast-feeding women or positive serum pregnancy test
• Uncontrolled brain metastases. Patients with brain metastases must be locally treated and the disease must be stable for at least one month at the time of enrolling
• Participation in any investigational drug study within 4 weeks preceding treatment start.
• Concurrent other malignancy at other sites or previous other cancer within the last 5 years, with the exception of adequately treated in situ carcinoma of cervix uteri or basal or squamous cell carcinoma of the skin or a contralateral breast cancer.
• Serious uncontrolled intercurrent infections
• Poor compliance